Alaunos Therapeutics, Inc.
TCRT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001107421
No open-market purchases or sales by Alaunos Therapeutics, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $204.4K in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 12:26 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $4.18M (83520.0% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | Mar 7, 2023 | Mar 30, 2022 |
| Revenue | $5.00K | $10.0K | $5.00K | $2.92M | $398.0K |
| Operating expenses | $4.23M | $4.82M | $34.3M | $38.0M | $77.9M |
| Research and development | $1.36M | $362.0K | $16.3M | $25.0M | $49.6M |
| Selling, general and administrative | $2.87M | $4.46M | $12.2M | $13.1M | $27.6M |
| Operating income | -$4.22M | -$4.81M | -$34.3M | -$35.1M | -$77.5M |
| Interest expense | – | – | $1.92M | $3.15M | $1.20M |
| Income tax | $0 | – | – | – | – |
| Net income | -$4.18M | -$4.68M | -$35.1M | -$37.7M | -$78.8M |
| EPS, basic | $-2.20 | $-2.92 | $-2.20 | $-0.17 | – |
| EPS, diluted | $-2.20 | $-2.92 | $-2.20 | $-0.17 | – |
| Weighted shares, basic | 1.95M | 1.60M | 16.0M | 217.1M | 214.4M |
| Weighted shares, diluted | 1.95M | 1.60M | 16.0M | 217.1M | – |
| Margins and growth | |||||
| Operating margin | -84500.0% | -48120.0% | -685340.0% | -1201.4% | -19484.7% |
| Net margin | -83520.0% | -46790.0% | -702800.0% | -1291.2% | -19786.7% |
| Revenue growth, year over year | −50.0% | +100.0% | −99.8% | +634.2% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | Mar 7, 2023 | Mar 30, 2022 |
| Cash and equivalents | $1.39M | $1.09M | $6.06M | $39.1M | $76.1M |
| Accounts receivable | $3.00K | $5.00K | $1.00K | $4.00K | $1.11M |
| Total current assets | $1.99M | $2.75M | $8.26M | $53.8M | $78.8M |
| Property, plant and equipment | $91.0K | $0 | $2.00K | $8.46M | $10.9M |
| Total assets | $2.97M | $2.75M | $8.26M | $64.9M | $94.9M |
| Accounts payable | $613.0K | $516.0K | $616.0K | $1.39M | $1.37M |
| Short-term debt | – | – | $0 | $16.8M | $7.87M |
| Total current liabilities | $813.0K | $692.0K | $1.96M | $24.2M | $16.0M |
| Long-term debt | – | $0 | $0 | $0 | $16.3M |
| Total liabilities | $813.0K | $692.0K | $1.96M | $26.4M | $36.8M |
| Shareholders' equity | $2.15M | $2.06M | $6.31M | $38.6M | $58.1M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | Mar 7, 2023 | Mar 30, 2022 |
| Operating cash flow | -$2.87M | -$4.97M | -$30.1M | -$29.2M | -$61.5M |
| Capital expenditures | $98.0K | $0 | $197.0K | $216.0K | $3.32M |
| Free cash flow | -$2.97M | -$4.97M | -$30.3M | -$29.4M | -$64.8M |
| Stock-based compensation | $796.0K | $435.0K | $2.80M | $3.53M | $10.8M |
| Share buybacks | – | – | $0 | $45.0K | – |
| Investing cash flow | -$98.0K | $0 | $1.35M | -$193.0K | -$3.32M |
| Financing cash flow | $3.26M | $0 | -$18.1M | $6.37M | $25.8M |
| Net change in cash | $294.0K | -$4.97M | -$46.9M | -$23.1M | -$39.0M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 15920.0% | 4350.0% | 56000.0% | 120.7% | 2707.0% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 14, 2026 | 2.54M | +15.7% | SEC |
| May 15, 2026 | 24.4M | +1,389.6% | SEC |
| Apr 30, 2026 | 2.40M | +46.5% | SEC |
| Mar 31, 2026 | 2.38M | +48.5% | SEC |
| Nov 14, 2025 | 2.23M | +39.4% | SEC |
| Aug 14, 2025 | 2.19M | +37.1% | SEC |
| May 15, 2025 | 1.64M | −89.8% | SEC |
| Apr 30, 2025 | 1.64M | −89.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-15 in Q1 2024 and 1-for-10 in Q3 2024.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.